Zynerba Press Releases

5 Sep 19 New Caregiver-Reported Data Further Validate the Use of the Aberrant Behavior Checklist Community: FXS Specific (ABC-CFXS) Subscales to Assess Core Behavioral Symptoms of Fragile X Syndrome (FXS)

3 Sep 19 Zynerba Pharmaceuticals to Present at Two Upcoming Conferences

29 Aug 19 Zynerba Pharmaceuticals Announces Poster Presentations at the 22nd Society for the Study of Behavioural Phenotypes (SSBP) Symposium

6 Aug 19 Zynerba Pharmaceuticals Announces Publication of Zygel™ (ZYN002) 12-week Open Label Fragile X Syndrome Data in the Journal of Neurodevelopmental Disorders

6 Aug 19 Zynerba Pharmaceuticals Reports Second Quarter 2019 Financial Results and Operational Highlights

31 Jul 19 Zynerba Pharmaceuticals to Present at Two Upcoming Conferences

1 Jul 19 Zynerba Pharmaceuticals Added to Russell 2000® and 3000® Indexes

11 Jun 19 Zynerba Pharmaceuticals Receives New U.S. Patent for Treatment of Autism Spectrum Disorder with Cannabidiol

30 May 19 Zynerba Pharmaceuticals to Present at FDA’s Public Hearing on Scientific Data and Information about Products Containing Cannabis or Cannabis-derived Compounds

29 May 19 Zynerba Pharmaceuticals Announces Initiation of Phase 2 Trial of Zygel™ in 22q11.2 Deletion Syndrome